Quidel coronavirus test granted emergency authorization

By LabPulse.com staff writers

March 18, 2020 -- Quidel has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to market its Lyra SARS-CoV-2 assay, a real-time reverse transcription polymerase chain reaction (RT-PCR) test for the novel coronavirus.

Quidel's Lyra line of products also includes PCR reagent kits. The Lyra SARS-CoV-2 assay is currently only available in the U.S., and it can be purchased through Quidel or Cardinal Health, the company said.

As COVID-19 crisis continues, other infectious diseases threaten
While the world remains focused on the coronavirus pandemic, other emerging infectious diseases are also circulating and are public health threats. Shara...
Studies find that coronavirus transmits before symptoms
The novel coronavirus can spread before patients are symptomatic, according to two new studies, one to be published in the May issue of Emerging Infectious...
Gottlieb: More coronavirus kits coming, but so is crisis
More kits to diagnose the coronavirus are going to be available soon, but that doesn't mean the U.S. is out of the woods, according to Dr. Scott...
AACC to build directory of COVID-19 test labs
The American Association for Clinical Chemistry (AACC) has started building a directory of clinical labs that offer testing for the coronavirus responsible...
FDA gives states, vendors more power in coronavirus fight
In a move it called an "unprecedented policy," the U.S. Food and Drug Administration (FDA) on March 16 once again relaxed its regulations on diagnostics...

Copyright © 2020 LabPulse.com

Last Updated np 3/18/2020 11:02:24 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current